{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:06:29Z","timestamp":1784318789845,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-024-04189-z","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T03:38:59Z","timestamp":1726803539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Add-on multidrug treatment based on quadruple therapy successfully treated worsening heart failure caused by anthracycline-induced cardiomyopathy in a survivor of cancer as a young adult: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Hirotaka","family":"Oda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihito","family":"Oyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Kashiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"4189_CR1","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1470-2045(16)30573-3","volume":"18","author":"DK Mayer","year":"2017","unstructured":"Mayer DK, Nasso SF, Earp JA. Defining cancer survivors, their needs, and perspectives on survivorship health care in the US. Lancet Oncol. 2017;18:e11\u20138.","journal-title":"Lancet Oncol"},{"key":"4189_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djz108","volume":"112","author":"Y Chen","year":"2020","unstructured":"Chen Y, Chow EJ, Oeffinger KC, Border WL, Leisenring WM, Meacham LR, et al. Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors. J Natl Cancer Inst. 2020;112:256\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"4189_CR3","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2015.65.5845","volume":"34","author":"C Chao","year":"2016","unstructured":"Chao C, Xu L, Bhatia S, Cooper R, Brar S, Wong FL, et al. Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer: the Kaiser permanente AYA cancer survivors study. J Clin Oncol. 2016;34:1626\u201333.","journal-title":"J Clin Oncol"},{"key":"4189_CR4","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","volume":"332","author":"SE Lipshultz","year":"1995","unstructured":"Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738\u201343.","journal-title":"N Engl J Med"},{"key":"4189_CR5","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138.","journal-title":"Circulation"},{"key":"4189_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:1757\u201380.","journal-title":"J Am Coll Cardiol"},{"key":"4189_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","volume":"10","author":"J Tromp","year":"2022","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022;10:73\u201384.","journal-title":"JACC Heart Fail"},{"key":"4189_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077\u201384.","journal-title":"N Engl J Med"},{"key":"4189_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.phrs.2017.03.016","volume":"127","author":"D Cappetta","year":"2018","unstructured":"Cappetta D, Rossi F, Piegari E, Quaini F, Berrino L, Urbanek K, et al. Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res. 2018;127:4\u201314.","journal-title":"Pharmacol Res"},{"key":"4189_CR10","doi-asserted-by":"publisher","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020. https:\/\/doi.org\/10.3389\/fcvm.2020.00026.","DOI":"10.3389\/fcvm.2020.00026"},{"key":"4189_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.763930","author":"P Banerjee","year":"2021","unstructured":"Banerjee P, Kotla S, Reddy Velatooru LR, Abe RJ, Davis EA, Cooke JP, et al. Senescence-associated secretory phenotype as a hinge between cardiovascular diseases and cancer. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2021.763930.","journal-title":"Front Cardiovasc Med"},{"key":"4189_CR12","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","volume":"34","author":"TM Suter","year":"2013","unstructured":"Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102\u201311.","journal-title":"Eur Heart J"},{"key":"4189_CR13","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883\u201393.","journal-title":"N Engl J Med"},{"key":"4189_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/CIRCRESAHA.110.226712","volume":"107","author":"LRV Castro","year":"2010","unstructured":"Castro LRV, Schittl J, Fischmeister R. Circ Res Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res. 2010;107:1232\u201340.","journal-title":"Circ Res"},{"key":"4189_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/ars.2015.6542","volume":"26","author":"S Vandenwijngaert","year":"2017","unstructured":"Vandenwijngaert S, Swinnen M, Walravens A-S, Beerens M, Gillijns H, Caluw\u00e9 E, et al. Decreased soluble guanylate cyclase contributes to cardiac dysfunction induced by chronic doxorubicin treatment in mice. Antioxid Redox Signal. 2017;26:153\u201364.","journal-title":"Antioxid Redox Signal"},{"key":"4189_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2023.04.057","volume":"82","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Filippatos G, Gustafsson F, et al. Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3\/3. J Am Coll Cardiol. 2023;82:559\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"4189_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.hlc.2019.02.004","volume":"29","author":"AN Patel","year":"2020","unstructured":"Patel AN, Southern WN. BNP-response to acute heart failure treatment identifies high-risk population. Heart Lung Circ. 2020;29:354\u201360.","journal-title":"Heart Lung Circ"},{"key":"4189_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cardfail.2023.02.009","volume":"29","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. J Cardiac Fail. 2023;29:787\u2013804.","journal-title":"J Cardiac Fail"},{"key":"4189_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"M B\u00f6hm","year":"2010","unstructured":"B\u00f6hm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886\u201394.","journal-title":"Lancet"},{"key":"4189_CR20","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"JC Tardif","year":"2011","unstructured":"Tardif JC, O\u2019Meara E, Komajda M, B\u00f6hm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507\u201315.","journal-title":"Eur Heart J"},{"key":"4189_CR21","first-page":"CD013004","volume":"11","author":"C Benstoem","year":"2020","unstructured":"Benstoem C, Kalvelage C, Breuer T, Heussen N, Marx G, Stoppe C, et al. Ivabradine as adjuvant treatment for chronic heart failure. Cochrane Database Syst Rev. 2020;11:CD013004.","journal-title":"Cochrane Database Syst Rev."},{"key":"4189_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/clc.23581","volume":"44","author":"RS Bryan","year":"2021","unstructured":"Bryan RS, Huang B, Liu G, Yang Y, Luo S. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: meta-analysis of randomized controlled trials. Clin Cardiol. 2021;44:463\u201371.","journal-title":"Clin Cardiol"},{"key":"4189_CR23","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ejhf.2836","volume":"25","author":"B Pieske","year":"2023","unstructured":"Pieske B, Pieske-Kraigher E, Lam CSP, Melenovsk\u00fd V, Sliwa K, Lopatin Y, et al. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy. Eur J Heart Fail. 2023;25:1012\u201321.","journal-title":"Eur J Heart Fail"},{"key":"4189_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jccase.2022.08.012","volume":"26","author":"T Imamura","year":"2022","unstructured":"Imamura T, Kinugawa K. Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure. J Cardiol Cases. 2022;26:429\u201331.","journal-title":"J Cardiol Cases"},{"key":"4189_CR25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18:1228\u201334.","journal-title":"Eur J Heart Fail."},{"key":"4189_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ehf2.12627","volume":"7","author":"A Mart\u00edn-Garcia","year":"2020","unstructured":"Mart\u00edn-Garcia A, L\u00f3pez-Fern\u00e1ndez T, Mitroi C, Chaparro-Mu\u00f1oz M, Moliner P, Martin-Garcia AC, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020;7:763\u20137.","journal-title":"ESC Heart Fail"},{"key":"4189_CR27","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04189-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T03:39:24Z","timestamp":1726803564000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04189-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4189"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04189-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Specialized Subcommittee of Niigata City General Hospital Ethics Committee approved this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"505"}}